Keywords: oral, formulation, allergan, tazarotene, rejected, fda, panel

Oral formulation of Allergan's tazarotene rejected by US FDA panel

Article | 19 July 2004

Print This

Even though it is already marketed as a gel and a cream, an oral form ofAllergan's tazarotene failed to pass ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in